Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children35510.24287/1726-1708-2020-19-2-184-192LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫSkin damage after the hematopoietic stem cell transplantation. Literature reviewПоражение кожных покровов при трансплантации гемопоэтических стволовых клеток. Обзор литературыhttps://orcid.org/0000-0003-1091-1521AlievT. Z.АлиевТ. З.
Russian Federation

Pediatric Oncologist Department of Pediatric Bone Marrow and Hematopoietic Stem Cell Transplantation of the Research Institute of Pediatric Oncology and Hematology,

Russia, 115478, Moscow, Kashirskoe Shosse, 23

врач-детский онколог отделения детской трансплантации костного мозга и гемопоэтических стволовых клеток,

115478, Москва, Каширское шоссе, 23

timaliev118@gmail.comhttps://orcid.org/0000-0003-2395-4045MachnevaE. B.МачневаЕ. Б.
Russian Federation
https://orcid.org/0000-0003-3797-5808SidorovaN. V.СидороваН. В.
Russian Federation
https://orcid.org/0000-0001-5911-553XBelyshevaT. S.БелышеваТ. С.
Russian Federation
https://orcid.org/0000-0002-1469-2365ValievT. T.ВалиевТ. Т.
Russian Federation
https://orcid.org/0000-0002-2945-284XKirgizovK. I.КиргизовК. И.
Russian Federation
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииRussian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Healthcare of Russian FederationОбособленное структурное подразделение Российская детская клиническая больница ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России020720201921841920207202002072020Copyright ©; 2020, «D. Rogachev NMRCPHOI»Copyright ©; 2020, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2020«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/355

Skin damage after hematopoietic stem cell transplantation (HSCT) is common and important diagnostic and therapeutic problem. The most significant causes of skin lesions in HSCT are drug toxicity, infections, and manifestations of skin acute and chronic “graft versus host” disease. Each of the complications can manifest in various forms, as well as to combine with others, exerting a significant negative effect on the patient’s condition, in severe cases posing a threat to the patient’s life. The article summarizes data on the etiology, features of pathogenesis, clinical forms, the main methods of diagnosis and therapy of the most common skin complications of HSCT.

Поражение кожи после трансплантации гемопоэтических стволовых клеток (ТГСК) встречается достаточно часто и представляет собой важную диагностическую и терапевтическую проблему. Наиболее значимыми причинами поражений кожи при ТГСК являются медикаментозная токсичность, инфекционные поражения, проявления кожной формы острой и хронической реакции «трансплантат против хозяина». Каждое из осложнений может проявляться в различной степени, а также сочетаться с другими, оказывая значимое отрицательное влияние на состояние пациента, в тяжелых случаях представляя угрозу для жизни больного. В статье обобщены данные об этиологии, особенностях патогенеза, клинических формах, основных методах диагностики и терапии наиболее часто встречающихся кожных осложнений при ТГСК.

skinhematopoietic stem cell transplantationlesiontoxicityimmune reactionsinfections“graft versus host” diseaseкожатрансплантация гемопоэтических стволовых клетокпоражениетоксичностьиммунные реакцииинфекцииреакция «трансплантат против хозяина»1. Paun O., Phillips T., Fu P., Novoa R.A., Honda K.S., Lu K.Q., Lazarus H.M. Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. Biol Blood Marrow Transplant 2013; 19 (8): 1204–9. DOI: 10.1016/j.bbmt.2013.05.006Paun O., Phillips T., Fu P., Novoa R.A., Honda K.S., Lu K.Q., Lazarus H.M. Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. Biol Blood Marrow Transplant 2013; 19 (8): 1204–9. DOI: 10.1016/j.bbmt.2013.05.0062. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945–56. doi: 10.1016/j.bbmt.2005.09.004Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945–56. doi: 10.1016/j.bbmt.2005.09.0043. Carreras E., Dufour C., Mohty M., Kröger N. (eds.). The EBMT Handbook. Hematopoietic Stem Cell Transplantation and Cellular Therapies. This Springer; 2019. 688 р.Carreras E., Dufour C., Mohty M., Kröger N. (eds.). The EBMT Handbook. Hematopoietic Stem Cell Transplantation and Cellular Therapies. This Springer; 2019. 688 р.4. Zeiser R., Penack O., Holler E., Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011; 89 (9): 833–45. DOI: 10.1007/s00109-011-0767-xZeiser R., Penack O., Holler E., Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011; 89 (9): 833–45. DOI: 10.1007/s00109-011-0767-x5. Sung A.D., Chao N.J. Acute graft-versushost disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013; 26 (3): 285–92. DOI: 10.1016/j.beha.2013.10.009Sung A.D., Chao N.J. Acute graft-versushost disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013; 26 (3): 285–92. DOI: 10.1016/j.beha.2013.10.0096. Pidala J., Sigdel T.K., Wang A., Hsieh S., Inamoto Y., Martin P.J., et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res 2017; 3 (1): 3–16. DOI: 10.1002/cjp2.58.eCollection 2017JanPidala J., Sigdel T.K., Wang A., Hsieh S., Inamoto Y., Martin P.J., et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res 2017; 3 (1): 3–16. DOI: 10.1002/cjp2.58.eCollection 2017Jan7. Saliba R.M., de Lima M., Giralt S., Andersson B., Khouri I.F., Hosing C., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109 (7):2751–8. DOI: 10.1182/blood-2006-07-034348Saliba R.M., de Lima M., Giralt S., Andersson B., Khouri I.F., Hosing C., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109 (7):2751–8. DOI: 10.1182/blood-2006-07-0343488. Румянцев А.Г., Масчан А.А., Балашов Д.Н., Скворцова Ю.В. Федеральные клинические рекомендации по лечению хронической реакции «трансплантат против хозяина» после трансплантации гемопоэтических стволовых клеток у детей. М.; 2015. (Электронный ресурс). URL: http://nodgo.org/sites/default/files/29(Г)хртгскР.pdf.Румянцев А.Г., Масчан А.А., Балашов Д.Н., Скворцова Ю.В. Федеральные клинические рекомендации по лечению хронической реакции «трансплантат против хозяина» после трансплантации гемопоэтических стволовых клеток у детей. М.; 2015. (Электронный ресурс). URL: http://nodgo.org/sites/default/files/29(Г)хртгскР.pdf.9. Min C.-K. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol 2011; 46(2): 80. DOI:10.5045/kjh.2011.46.2.80Min C.-K. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol 2011; 46(2): 80. DOI:10.5045/kjh.2011.46.2.8010. Shulman H.M., Kleiner D., Lee S.J., Morton T., Pavletic S.Z., Farmer E., et al. Histopathologic diagnosis of chronic graftversus- host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12 (1): 31–47. DOI: 10.1016/j.bbmt.2005.10.023Shulman H.M., Kleiner D., Lee S.J., Morton T., Pavletic S.Z., Farmer E., et al. Histopathologic diagnosis of chronic graftversus- host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12 (1): 31–47. DOI: 10.1016/j.bbmt.2005.10.02311. Jaffee B.D., Claman H.N. Chronic graftversus- host disease (GvHD) as a model for scleroderma. Cellular Immunology 1983; 77 (1): 1–12. DOI: 10.1016/0008-8749(83)90001-1Jaffee B.D., Claman H.N. Chronic graftversus- host disease (GvHD) as a model for scleroderma. Cellular Immunology 1983; 77 (1): 1–12. DOI: 10.1016/0008-8749(83)90001-112. Murata T., Husain S.R., Mohri H., Puri R.K. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998; 10 (8): 1103–10. DOI: 10.1093/intimm/10.8.1103Murata T., Husain S.R., Mohri H., Puri R.K. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998; 10 (8): 1103–10. DOI: 10.1093/intimm/10.8.110313. Atamas S.P., White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15 (6): 772–7. DOI: 10.1097/00002281-200311000-00015Atamas S.P., White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15 (6): 772–7. DOI: 10.1097/00002281-200311000-0001514. Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.e1. DOI: 10.1016/j.bbmt.2014.12.001Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.e1. DOI: 10.1016/j.bbmt.2014.12.00115. Jang S., Kim I.S., Youn S.W. Chronic graftversus- host disease mimicking psoriasis in a patient with hemophagocytic lymphohistiocytosis. Ann Dermatol 2016; 28 (1): 90–3. DOI: 10.5021/ad.2016.28.1.90Jang S., Kim I.S., Youn S.W. Chronic graftversus- host disease mimicking psoriasis in a patient with hemophagocytic lymphohistiocytosis. Ann Dermatol 2016; 28 (1): 90–3. DOI: 10.5021/ad.2016.28.1.9016. Ceovic´ R., Desnica L., Pulanic´ D., Serventi Seiwerth R., Ilic´ I., Grce M., et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J 2016; 57 (3): 229–38. DOI: 10.3325/cmj.2016.57.229Ceovic´ R., Desnica L., Pulanic´ D., Serventi Seiwerth R., Ilic´ I., Grce M., et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J 2016; 57 (3): 229–38. DOI: 10.3325/cmj.2016.57.22917. Kim S.J., Choi J.M., Kim J.E., Cho B.K., Kim D.W., Park H.J. Clinicopathologic characteristics of cutaneous graft-versus- host disease: a retrospective study in Korean patients. Int J Dermatol 2010; 49 (12): 1386–92. DOI: 10.1111/j.1365-4632.2010.04552.xKim S.J., Choi J.M., Kim J.E., Cho B.K., Kim D.W., Park H.J. Clinicopathologic characteristics of cutaneous graft-versus- host disease: a retrospective study in Korean patients. Int J Dermatol 2010; 49 (12): 1386–92. DOI: 10.1111/j.1365-4632.2010.04552.x18. Manalo I.F., Miller I.A., Davies L.S. More immune dysregulation: sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. JAAD Case Rep 2016; 2 (2): 138–40. DOI: 10.1016/j.jdcr.2016.01.008Manalo I.F., Miller I.A., Davies L.S. More immune dysregulation: sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. JAAD Case Rep 2016; 2 (2): 138–40. DOI: 10.1016/j.jdcr.2016.01.00819. Paczesny S., Braun T.M., Levine J.E., Hogan J., Crawford J., Coffing B., et al. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med 2010; 2 (13): 1–19. DOI: 10.1126/scitranslmed.3000406Paczesny S., Braun T.M., Levine J.E., Hogan J., Crawford J., Coffing B., et al. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med 2010; 2 (13): 1–19. DOI: 10.1126/scitranslmed.300040620. Levine J.E., Braun T.M., Harris A.C., Holler E., Taylor A., Miller H., et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015; 2 (1): е21–9. DOI: 10.1016/S2352-3026(14)00035-0Levine J.E., Braun T.M., Harris A.C., Holler E., Taylor A., Miller H., et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015; 2 (1): е21–9. DOI: 10.1016/S2352-3026(14)00035-021. Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stemcell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7 (2): e157–67. DOI: 10.1016/S2352-3026(19)30256-X.Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stemcell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7 (2): e157–67. DOI: 10.1016/S2352-3026(19)30256-X.22. Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59 (3): 524–9. DOI: 10.1016/j.jaad.2008.05.018.Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59 (3): 524–9. DOI: 10.1016/j.jaad.2008.05.018.23. Horn T.D., Beveridge R.A., Egorin M.J., Abeloff M.D., Hood A.F. Observations and proposed mechanism of N,N9,N99-triethyl-enethiophosphoramide (thiotepa)-induced hyperpigmenta-tion. Arch Dermatol 1989; 125 (4): 524–7.Horn T.D., Beveridge R.A., Egorin M.J., Abeloff M.D., Hood A.F. Observations and proposed mechanism of N,N9,N99-triethyl-enethiophosphoramide (thiotepa)-induced hyperpigmenta-tion. Arch Dermatol 1989; 125 (4): 524–7.24. Mays S.R., Kunishige J.H., Truong E., Kontoyiannis D.P., Hymes S.R. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 2007; 26 (3): 155–62. DOI: 10.1016/j.sder.2007.09.004Mays S.R., Kunishige J.H., Truong E., Kontoyiannis D.P., Hymes S.R. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 2007; 26 (3): 155–62. DOI: 10.1016/j.sder.2007.09.00425. Betts B.C., Young J.A., Ustun C., Ustun C., Cao Q., Weisdorf D.J. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17 (10): 1562–8. DOI: 10.1016/j.bbmt.2011.04.004Betts B.C., Young J.A., Ustun C., Ustun C., Cao Q., Weisdorf D.J. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17 (10): 1562–8. DOI: 10.1016/j.bbmt.2011.04.00426. Dignan F.L., Clark A., Amrolia P., Cornish J., Jackson G., Mahendra P., et al. Diagnosis and management of acute graftversus- host disease. Br J Haematol 2012; 158 (1): 30–45. DOI: 10.1111/j.1365-2141.2012.09129.xDignan F.L., Clark A., Amrolia P., Cornish J., Jackson G., Mahendra P., et al. Diagnosis and management of acute graftversus- host disease. Br J Haematol 2012; 158 (1): 30–45. DOI: 10.1111/j.1365-2141.2012.09129.x27. Rosman I.S., Lloyd B.M., Hayashi R.J., Bayliss S.J. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58 (4): 575–8. DOI:10.1016/j.jaad.2007.12.037Rosman I.S., Lloyd B.M., Hayashi R.J., Bayliss S.J. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58 (4): 575–8. DOI:10.1016/j.jaad.2007.12.03728. Balsat M., Pillet S., Tavernier E., Cacheux V., Escuret V., Moluçon-Chabrot C., et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect 2019; 79 (1): 36–42. DOI: 10.1016/j.jinf.2019.05.001Balsat M., Pillet S., Tavernier E., Cacheux V., Escuret V., Moluçon-Chabrot C., et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect 2019; 79 (1): 36–42. DOI: 10.1016/j.jinf.2019.05.00129. Miura T., Kikuchi N., Ohtsuka M., Yamamoto T. Varicella in a patient with drug-induced hypersensitivity syndrome developed after autologous peripheral stem cell transplantation. Int J Dermatol 2018; 57 (9): e71–e73. DOI: 10.1111/ijd.14091Miura T., Kikuchi N., Ohtsuka M., Yamamoto T. Varicella in a patient with drug-induced hypersensitivity syndrome developed after autologous peripheral stem cell transplantation. Int J Dermatol 2018; 57 (9): e71–e73. DOI: 10.1111/ijd.14091